PORACTON MEMBRANE

Baxter

Gambro revaclear

A SIMPLE CHOICE FOR YOUR PATIENTS*

The Gambro REVACLEAR dialyzer provides high flux dialysis treatment using the PORACTON membrane. The precise and carefully engineered membrane aids retention of essential proteins, delivers high performance and effective treatments, and may promote biocompatibility.[1,2]

EXCEPTIONAL PERFORMANCE[3]

- Removal of small and middle molecules in high flux hemodialysis shown statistically equivalent to a 22% larger surface area dialyzer[1,3,4]
- Designed to improve biocompatibility for your patients[1,2]

EFFICIENT AND CONVENIENT

- Drive efficiencies with two size options to meet your patients' clearance needs[5]
- Removable patient label to help streamline documentation
- Low priming and rinse-back volumes support to minimize sodium loading by dialysis[6,7,8,**]

COMPACT AND COST EFFICIENT

- Effective packaging can simplify storage and handling
- Reduced saline and concentrate requirements could provide cost savings to your clinic[6,7]
- Designed to minimize biohazardous waste and environmental burden[9]

Revaclear 300 and 400 dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis or hemodiafiltration.

TYPICAL PATIENT PROFILE:
GENERAL HEMODIALYSIS (HD) PATIENT POPULATION

* Based on modeling data from the Gambro dose calculator tool

** Compared to a larger dialyzer

Making possible personal.

Gambro REVACLEAR Dialyzer

CLEARANCE IN VITRO (ml/min) ± 10%

	REVACLEAR 300				REVACLEAR 400				
Q_B (ml/min)	200	300	400	500	200	300	400	500	600
Hemodialysis Q_D=500 ml/min, UF=0 ml/min									
Urea	196	272	323	356	198	281	338	375	401
Creatinine	191	256	298	326	195	267	315	348	370
Phosphate	185	242	278	303	191	255	297	326	346
Vitamin B_{12}	146	174	191	204	158	191	213	228	240
Hemodiafiltration Q_D=500 ml/min, UF=60 ml/min									
Urea	198	280	336	374	199	286	348	390	420
Creatinine	195	266	312	344	197	274	326	361	387
Phosphate	191	253	293	320	194	263	308	339	361
Vitamin B_{12}	161	191	210	222	168	204	226	241	253
Hemodiafiltration Q_D=800 ml/min, UF=60 ml/min									
Urea	199	289	361	416	200	293	372	434	482
Creatinine	197	278	338	382	199	285	352	403	442
Phosphate	195	267	318	355	197	276	334	377	411
Vitamin B_{12}	167	204	227	243	175	218	245	265	281

SPECIFICATIONS		
KoA for urea*	1186	1439
UF-coefficient in vitro** (ml/h·mmHg)	48	54
Blood flow rate (ml/min)	200-500	200-600
Dialysate flow rate (ml/min)	300-800	300-800
Membrane		
Effective surface area (m^2)	1.4	1.8
Wall thickness (µm)	35	35
Inner diameter (µm)	190	190
Blood compartment volume (ml)	74	93
Residual blood volume (ml)	<1	
Recommended priming volume for rinsing (ml)	≥300	
Maximum TMP (mmHg)	600	
Sieving coefficient* **		
Vitamin B_{12}	1.0	
Inulin	1.0	
$ß_2$-microglobulin	0.7	
Albumin	<0.01	
Material		
Membrane material	PORACTON (PAES / PVP) (BPA-free)	
Housing material	Polycarbonate (PC)	
Potting	Polyurethane (PUR)	
O-ring	Silicone rubber	
Sterilization agent	Steam	
Quantity per case	24	

* Q_B=300ml/min, Q_D=500ml/min, UF=0ml/min ** Bovine blood, Hct 32%, Pct 60 g/l, 37°C *** According to ISO 8637. Typical values measured with REVACLEAR 300

CE 0086

For the safe and proper use of the Revaclear dialyzers, refer to the warnings and cautions, adverse events and detailed directions for use.

Baxter Corporation
7125 Mississauga Road
Mississauga, ON L5N 0C2

1. Data on file. May 2013. Nilsson LG, Beck W and Bosch J. REVACLEAR White Paper. **2.** Data on file. 2012. Biological and Chemical Evaluation Report in Accordance to GWIN 11-09. **3.** Mauric A, et al. Poster presented at 50th ERA-EDTA congress. Istanbul (Turkey). 2013. [Poster SP401]. **4.** Bhimani JP, et al. Nephrol Dial Transplant 2010; 25:3990–3995. **5.** Data on file. 2015. Calculations performed using the Gambro dose calculator tool. **6.** Ronco C, et al. Nephrol Dial Transplant 2003; 18(Suppl 7):vii10–vii20. **7.** REVACLEAR dialyzer priming guide 2009; 306150152_C). **8.** Thijssen S, et al. Contrib Nephrol 2011; 171:84–91. **9.** Data on file. 2015. Biohazardous waste cost calculation.

CAMP/MG135/16-0002 SEPT 2016